These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 30033559)

  • 1. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
    Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
    J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.
    Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L
    Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.
    Ten Brink DC; Martin-Hughes R; Minnery ME; Osborne AJ; Schmidt HA; Dalal S; Green KE; Ramaurtarsing R; Wilson DP; Kelly SL
    PLoS One; 2022; 17(5):e0268240. PubMed ID: 35617169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
    Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
    AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a pre-exposure prophylaxis programme for men who have sex with men and transgender women in Thailand: learning through the HIV prevention cascade lens.
    Ramautarsing RA; Meksena R; Sungsing T; Chinbunchorn T; Sangprasert T; Fungfoosri O; Meekrua D; Sumalu S; Pasansai T; Bunainso W; Wongsri T; Mainoy N; Colby D; Avery M; Mills S; Vannakit R; Phanuphak P; Phanuphak N
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25540. PubMed ID: 32602660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.
    Hu QH; Meyers K; Xu JJ; Chu ZX; Zhang J; Ding HB; Han XX; Jiang YJ; Geng WQ; Shang H
    BMC Infect Dis; 2019 Jul; 19(1):663. PubMed ID: 31345169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel.
    Ginsberg GM; Chemtob D
    BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
    Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
    BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
    Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
    J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan.
    Mizushima D; Nagai Y; Mezzio D; Harada K; Piao Y; Barnieh L; El Moustaid F; Cawson M; Taniguchi T
    J Med Econ; 2023; 26(1):886-893. PubMed ID: 37421417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
    Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
    Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
    Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016.
    Ong KJ; Desai S; Field N; Desai M; Nardone A; van Hoek AJ; Gill ON
    Euro Surveill; 2017 Oct; 22(42):. PubMed ID: 29067902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
    Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-level effectiveness of pre-exposure prophylaxis for HIV prevention among men who have sex with men in Montréal (Canada): a modelling study of surveillance and survey data.
    Doyle CM; Milwid RM; Cox J; Xia Y; Lambert G; Tremblay C; Otis J; Boily MC; Baril JG; Thomas R; Blais AD; Trottier B; Grace D; Moore DM; Mishra S; Maheu-Giroux M
    J Int AIDS Soc; 2023 Dec; 26(12):e26194. PubMed ID: 38054579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
    Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
    AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
    Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
    J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.
    Mitchell KM; Lépine A; Terris-Prestholt F; Torpey K; Khamofu H; Folayan MO; Musa J; Anenih J; Sagay AS; Alhassan E; Idoko J; Vickerman P
    AIDS; 2015 Sep; 29(15):2035-44. PubMed ID: 26355574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.
    Luz PM; Osher B; Grinsztejn B; Maclean RL; Losina E; Stern ME; Struchiner CJ; Parker RA; Freedberg KA; Mesquita F; Walensky RP; Veloso VG; Paltiel AD
    J Int AIDS Soc; 2018 Mar; 21(3):e25096. PubMed ID: 29603888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment.
    Reyes-Urueña J; Campbell C; Diez E; Ortún V; Casabona J
    AIDS Care; 2018 Jun; 30(6):784-792. PubMed ID: 29262694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.